Needham upgraded Penumbra (PEN) to Buy from Hold with a $326 price target The firm expects the company’s growth in 2026 to meaningfully accelerate due to the upcoming Thunderbolt and Ruby XL launches, STORM-PE trial results, and easing of headwinds in China. Thunderbolt should nearly double Penumbra’s revenue per stroke procedure while driving stronger neuro thrombectomy growth and further gross margin improvement, the analyst tells investors in a research note. Needham also believes Penumbra is positioned for meaningful upside to consensus 2026 earnings estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra’s Growth Potential: Buy Rating Backed by Thunderbolt Launch and Market Expansion
- Penumbra added to Q4 2025 Tactical Ideas List at Wells Fargo
- Positive Outlook for Penumbra Amid Promising STORM PE Trial and Expanding Pulmonary Embolism Market
- Positive Outlook on Penumbra’s Stock Driven by Ruby XL’s Market Impact and Efficiency Gains
- Elf Beauty downgraded, Zscaler upgraded: Wall Street’s top analyst calls